Advertisement
AZN vs LLY
Which Stock Would AI Choose? AstraZeneca (AZN) vs. Eli Lilly (LLY) Stock Comparison
Key Takeaways
- AZN and LLY represent leading pharmaceutical companies with distinct therapeutic focuses: oncology and respiratory for AZN, and diabetes and obesity for LLY.
- Recent market activity shows LLY maintaining stronger price momentum driven by GLP-1 product demand, while AZN experienced more volatility amid earnings and pipeline updates.
- AZN reported Q2 2026 earnings with core EPS beats and EU regulatory approvals in oncology, supporting its diversified portfolio.
- LLY continues to benefit from robust volume growth in key medicines, with raised full-year guidance reflecting sustained market positioning.
- Sector exposure differs notably, with AZN facing trial-related pressures and LLY navigating competitive and regulatory dynamics in weight-loss treatments.
- Relative performance in recent weeks highlights trade-offs between stability in established franchises and high-growth opportunities in metabolic diseases.
Introduction
Pharmaceutical stocks AZN and LLY offer investors exposure to innovative drug development in high-demand therapeutic areas. This comparison examines their business models, recent stock behavior, and market positioning to assist traders and long-term investors evaluating relative opportunities within the healthcare sector. Professionals monitoring earnings momentum, regulatory developments, and sector-specific catalysts may find the analysis relevant when assessing portfolio allocation between established oncology players and leaders in metabolic health solutions.
AZN Overview and Recent Performance
AstraZeneca develops and commercializes medicines primarily in oncology, cardiovascular, renal, metabolism, and respiratory diseases. In recent market activity, the stock has shown mixed price behavior influenced by quarterly results and pipeline news. The company reported Q2 2026 earnings featuring a core EPS beat alongside a modest revenue miss, accompanied by EU approval for a new cancer treatment. Sentiment has been shaped by these positive regulatory steps offset by occasional trial setbacks and broader sector movements, contributing to fluctuations observed over recent weeks.
LLY Overview and Recent Performance
Eli Lilly focuses on treatments for diabetes, obesity, oncology, and neuroscience. The stock has demonstrated resilient performance in recent market activity, supported by strong demand for its GLP-1 receptor agonists. Following impressive prior-quarter results and guidance increases, the company has highlighted momentum in new medicines. Developments such as additional Phase 3 data for next-generation obesity candidates have reinforced positioning, though competitive pressures remain a factor in overall sentiment during recent weeks.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of AI-powered trading bots designed for various market conditions. Tickeron offers hundreds of AI Trading Bots that trade thousands of different tickers across equities, options, and other instruments. Only the highest-performing and most suitable bots for prevailing conditions earn placement in this trending section. Available bots feature diverse trading styles, strategies, timeframes, performance metrics, and ticker sets, with historical statistics often spanning win rates, drawdowns, and returns in ranges that can help users evaluate fit. The platform provides transparent data on each bot’s characteristics. Explore Trending AI Robots to review current options.
Head-to-Head Comparison
AZN operates with a broad therapeutic pipeline emphasizing oncology and established franchises, providing relative diversification but exposing it to clinical and regulatory variability. In contrast, LLY derives significant growth from its concentrated position in GLP-1 therapies for diabetes and obesity, delivering higher recent momentum at the cost of greater competitive intensity. Business models differ in scale of revenue concentration, with LLY showing outsized volume-driven expansion and AZN relying on steady contributions across multiple areas. Risk factors include trial outcomes for AZN versus market access and litigation considerations for LLY. Market sentiment has favored LLY’s growth narrative in recent periods, while AZN offers a more measured profile amid sector rotation.
Tickeron AI Verdict
Based on observable factors such as trend consistency and catalyst visibility, Tickeron’s AI would currently assign a higher probabilistic preference to LLY due to sustained momentum in high-growth categories and supportive volume trends. AZN presents a balanced alternative with potential stability from diversified approvals, though recent volatility suggests a more cautious positioning. This assessment reflects relative market dynamics without implying definitive outcomes.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AZN is a Buy and LLY is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AZN’s FA Score shows that 2 FA rating(s) are green whileLLY’s FA Score has 2 green FA rating(s).
- AZN’s FA Score: 2 green, 3 red.
- LLY’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AZN’s TA Score shows that 5 TA indicator(s) are bullish while LLY’s TA Score has 2 bullish TA indicator(s).
- AZN’s TA Score: 5 bullish, 5 bearish.
- LLY’s TA Score: 2 bullish, 6 bearish.
Price Growth
AZN (@Pharmaceuticals: Major) experienced а +0.22% price change this week, while LLY (@Pharmaceuticals: Major) price change was -3.95% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.41%. For the same industry, the average monthly price growth was -2.13%, and the average quarterly price growth was +3.17%.
Reported Earning Dates
AZN is expected to report earnings on Oct 30, 2026.
LLY is expected to report earnings on Aug 05, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-1.41% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| AZN | LLY | AZN / LLY | |
| Capitalization | 264B | 1.02T | 26% |
| EBITDA | 20.4B | 36.2B | 56% |
| Gain YTD | 84.532 | 7.263 | 1,164% |
| P/E Ratio | 25.40 | 40.81 | 62% |
| Revenue | 61.4B | 72.2B | 85% |
| Total Cash | 4.97B | 5.28B | 94% |
| Total Debt | 32.2B | 43.4B | 74% |
AZN | LLY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 9 | 18 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 11 Undervalued | 60 Fair valued | |
PROFIT vs RISK RATING 1..100 | 15 | 12 | |
SMR RATING 1..100 | 44 | 12 | |
PRICE GROWTH RATING 1..100 | 44 | 43 | |
P/E GROWTH RATING 1..100 | 60 | 84 | |
SEASONALITY SCORE 1..100 | 55 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AZN's Valuation (11) in the Pharmaceuticals Major industry is somewhat better than the same rating for LLY (60). This means that AZN’s stock grew somewhat faster than LLY’s over the last 12 months.
LLY's Profit vs Risk Rating (12) in the Pharmaceuticals Major industry is in the same range as AZN (15). This means that LLY’s stock grew similarly to AZN’s over the last 12 months.
LLY's SMR Rating (12) in the Pharmaceuticals Major industry is in the same range as AZN (44). This means that LLY’s stock grew similarly to AZN’s over the last 12 months.
LLY's Price Growth Rating (43) in the Pharmaceuticals Major industry is in the same range as AZN (44). This means that LLY’s stock grew similarly to AZN’s over the last 12 months.
AZN's P/E Growth Rating (60) in the Pharmaceuticals Major industry is in the same range as LLY (84). This means that AZN’s stock grew similarly to LLY’s over the last 12 months.
| AZN | LLY | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 47% | 4 days ago 70% |
| Stochastic ODDS (%) | 4 days ago 43% | 4 days ago 75% |
| Momentum ODDS (%) | 4 days ago 60% | 4 days ago 66% |
| MACD ODDS (%) | 4 days ago 62% | 4 days ago 47% |
| TrendWeek ODDS (%) | 4 days ago 57% | 4 days ago 60% |
| TrendMonth ODDS (%) | 4 days ago 46% | 4 days ago 58% |
| Advances ODDS (%) | 6 days ago 58% | 7 days ago 70% |
| Declines ODDS (%) | 4 days ago 45% | 4 days ago 56% |
| BollingerBands ODDS (%) | 4 days ago 53% | 6 days ago 53% |
| Aroon ODDS (%) | 5 days ago 51% | 4 days ago 75% |
Advertisement
AZN and
Correlation & Price change
A.I.dvisor indicates that over the last year, AZN has been loosely correlated with BIIB. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if AZN jumps, then BIIB could also see price increases.
| Ticker / NAME | Correlation To AZN | 1D Price Change % | ||
|---|---|---|---|---|
| AZN | 100% | -0.99% | ||
| BIIB - AZN | 48% Loosely correlated | -2.40% | ||
| LLY - AZN | 44% Loosely correlated | -0.53% | ||
| GILD - AZN | 39% Loosely correlated | -0.82% | ||
| NVS - AZN | 30% Poorly correlated | -1.45% | ||
| MRK - AZN | 28% Poorly correlated | +0.32% | ||
More | ||||